Next, melanoma cells were exposed to either PLX-4720 or PD-184352 (MEK1/2 inhibitor) in the presence of increasing concentrations (6.25–50 ng/mL) of recombinant HGF, HGF-neutralizing antibodies, or crizotinib, a MET inhibitor. Here, MET is linked to melanoma.